Pfizer (NYSE:PFE) failed pursuit of AstraZeneca has dominated the news all month, but its filing for accelerated approval of palbociclib is nearly as important. This breast cancer drug, with peak sales estimates over $5 billion, could get an early date with the FDA. Pfizer will file for accelerated approval based on strong phase 2 data.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass discuss the excitement around palbo, its importance to Pfizer, and a hidden stock that will get an 8% royalty on the drugs potentially massive sales.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.